Investor Presentaiton
Balanced Approach to Capital Allocation
Cash flow from Operations $B
$3.7
$3.3
$3.0
$1.9
$4.8
Business
Development
Q3
2022
Q4
Q1
Q2
Q3
2022 2023
2023 2023
$B
Q3 2023
Total Cash*
-$8.0B
~$37.6B
• Prioritize opportunities to further diversify
portfolio & strengthen long-term outlook
- Entered into agreement to acquire Mirati
Therapeutics; planned close by 1H 2024
Balance Sheet
Strength
Maintain strong investment-grade credit rating
Returning Cash
to Shareholders
Total Debt
Strong operating cash flow generation
ll Bristol Myers Squibb Q3 2023 Results
*Cash includes cash, cash equivalents and marketable debt securities
**Subject to Board approval
Note: YTD operating cash may not add due to rounding
•
Continued annual dividend growth**
Opportunistic share repurchase
- Executed $4B ASR Agreements in Q3'23
- Approx. $2B remaining share authorization
Not for Product Promotional Use
20View entire presentation